Jan H M Schellens


Ontology type: schema:Person     


Person Info

NAME

Jan H M

SURNAME

Schellens

Publications in SciGraph latest 50 shown

  • 2019-03 Therapeutic Drug Monitoring of Oral Anti-Hormonal Drugs in Oncology in CLINICAL PHARMACOKINETICS
  • 2019-03 Impact of age on exposure to oral antiandrogen therapies in clinical practice in PROSTATE CANCER AND PROSTATIC DISEASES
  • 2019-02 Impact of Older Age on the Exposure of Paclitaxel: a Population Pharmacokinetic Study in PHARMACEUTICAL RESEARCH
  • 2018-12-26 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours in BRITISH JOURNAL OF CANCER
  • 2018-12 Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose in INVESTIGATIONAL NEW DRUGS
  • 2018-11 Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen in BREAST CANCER RESEARCH AND TREATMENT
  • 2018-09 Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-08 Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-06 Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2018-06 The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2018-05 A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-05 Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial in CLINICAL PHARMACOKINETICS
  • 2018-04 PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer in CLINICAL PHARMACOKINETICS
  • 2018-03 EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid in JOURNAL OF NEURO-ONCOLOGY
  • 2018-02 Clinical Pharmacokinetics of Systemically Administered Antileishmanial Drugs in CLINICAL PHARMACOKINETICS
  • 2018-01 Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018-01 Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2018 Variabiliteit in ‘gevoeligheid’ voor farmaca in ALGEMENE FARMACOLOGIE
  • 2018-01 A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-12 Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2017-12 Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer in INVESTIGATIONAL NEW DRUGS
  • 2017-12 Thermal study of pazopanib hydrochloride in JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY
  • 2017-10 Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies in THE PHARMACOGENOMICS JOURNAL
  • 2017-10 Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer in INVESTIGATIONAL NEW DRUGS
  • 2017-09 High-Tech Drugs in Creaky Formulations in PHARMACEUTICAL RESEARCH
  • 2017-09 Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing in CLINICAL PHARMACOKINETICS
  • 2017-08 Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II in INVESTIGATIONAL NEW DRUGS
  • 2017-05-23 Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity in BRITISH JOURNAL OF CANCER
  • 2017-05-17 Klinische onderzoeksmethodologie in de oncologie in LEERBOEK ONCOLOGIE
  • 2017-03 Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients in CLINICAL PHARMACOKINETICS
  • 2017-02 Clinical pharmacokinetics of an amorphous solid dispersion tablet of elacridar in DRUG DELIVERY AND TRANSLATIONAL RESEARCH
  • 2017 Geneesmiddelen in FARMACOLOGIE
  • 2017 Maligne aandoeningen in FARMACOLOGIE
  • 2016-12 A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial in TRIALS
  • 2016-10 Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-10 Pharmacokinetics and excretion of 14C-omacetaxine in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2016-06 A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2016-06 A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors in INVESTIGATIONAL NEW DRUGS
  • 2016-06 The performance of model-based versus rule-based phase I clinical trials in oncology in JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
  • 2016-06 Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison in INVESTIGATIONAL NEW DRUGS
  • 2016-06 Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2016-04 A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignancies in INVESTIGATIONAL NEW DRUGS
  • 2016-03-16 A phosphotyrosine switch regulates organic cation transporters in NATURE COMMUNICATIONS
  • 2016-03 Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer in THE AAPS JOURNAL
  • 2016-03 Strategies to target drugs to gliomas and CNS metastases of solid tumors in JOURNAL OF NEUROLOGY
  • 2016-02 Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study in INVESTIGATIONAL NEW DRUGS
  • 2015-12 Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis in BMC MEDICINE
  • 2015-12 Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction in CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • 2015-12 Essential medicines for breast cancer in low and middle income countries in BMC CANCER
  • 2015-12 Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer in INVESTIGATIONAL NEW DRUGS
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.430814.a", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10419.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7107.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5590.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.1013.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.497530.c", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5477.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.28803.31", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.10417.33", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.476460.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411326.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.412966.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.477604.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5132.5", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.413508.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4494.d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415930.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.267309.9", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.419619.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.3575.4", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.415214.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.428696.7", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.152326.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416050.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4777.3", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.18886.3f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.416266.1", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5645.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.5650.6", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.424926.f", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.9654.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.7692.a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417581.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.16872.3a", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.4305.2", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.13648.38", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417815.e", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.417068.c", 
            "type": "Organization"
          }
        ], 
        "familyName": "Schellens", 
        "givenName": "Jan H M", 
        "id": "sg:person.013575273137.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2019-03-07T13:34", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-researchers-20181010/20181011/dim_researchers/base/researchers_1362.json", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.013575273137.17'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.013575273137.17'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.013575273137.17'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.013575273137.17'


     

    This table displays all metadata directly associated to this object as RDF triples.

    90 TRIPLES      10 PREDICATES      48 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.013575273137.17 schema:affiliation Nebf9f5c6cecd4e50b25e0e7f21f94746
    2 https://www.grid.ac/institutes/grid.1013.3
    3 https://www.grid.ac/institutes/grid.10417.33
    4 https://www.grid.ac/institutes/grid.10419.3d
    5 https://www.grid.ac/institutes/grid.13648.38
    6 https://www.grid.ac/institutes/grid.152326.1
    7 https://www.grid.ac/institutes/grid.16872.3a
    8 https://www.grid.ac/institutes/grid.18886.3f
    9 https://www.grid.ac/institutes/grid.267309.9
    10 https://www.grid.ac/institutes/grid.28803.31
    11 https://www.grid.ac/institutes/grid.3575.4
    12 https://www.grid.ac/institutes/grid.411326.3
    13 https://www.grid.ac/institutes/grid.412966.e
    14 https://www.grid.ac/institutes/grid.413508.b
    15 https://www.grid.ac/institutes/grid.415214.7
    16 https://www.grid.ac/institutes/grid.415930.a
    17 https://www.grid.ac/institutes/grid.416050.6
    18 https://www.grid.ac/institutes/grid.416266.1
    19 https://www.grid.ac/institutes/grid.417068.c
    20 https://www.grid.ac/institutes/grid.417581.e
    21 https://www.grid.ac/institutes/grid.417815.e
    22 https://www.grid.ac/institutes/grid.419619.2
    23 https://www.grid.ac/institutes/grid.424926.f
    24 https://www.grid.ac/institutes/grid.428696.7
    25 https://www.grid.ac/institutes/grid.4305.2
    26 https://www.grid.ac/institutes/grid.4494.d
    27 https://www.grid.ac/institutes/grid.476460.7
    28 https://www.grid.ac/institutes/grid.477604.6
    29 https://www.grid.ac/institutes/grid.4777.3
    30 https://www.grid.ac/institutes/grid.497530.c
    31 https://www.grid.ac/institutes/grid.5132.5
    32 https://www.grid.ac/institutes/grid.5477.1
    33 https://www.grid.ac/institutes/grid.5590.9
    34 https://www.grid.ac/institutes/grid.5645.2
    35 https://www.grid.ac/institutes/grid.5650.6
    36 https://www.grid.ac/institutes/grid.7107.1
    37 https://www.grid.ac/institutes/grid.7692.a
    38 https://www.grid.ac/institutes/grid.9654.e
    39 schema:familyName Schellens
    40 schema:givenName Jan H M
    41 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013575273137.17
    42 schema:sdDatePublished 2019-03-07T13:34
    43 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    44 schema:sdPublisher N097dec3d2fc64b98ab7b2c6eb8721e48
    45 sgo:license sg:explorer/license/
    46 sgo:sdDataset persons
    47 rdf:type schema:Person
    48 N097dec3d2fc64b98ab7b2c6eb8721e48 schema:name Springer Nature - SN SciGraph project
    49 rdf:type schema:Organization
    50 Nebf9f5c6cecd4e50b25e0e7f21f94746 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
    51 sgo:isCurrent true
    52 rdf:type schema:OrganizationRole
    53 https://www.grid.ac/institutes/grid.1013.3 schema:Organization
    54 https://www.grid.ac/institutes/grid.10417.33 schema:Organization
    55 https://www.grid.ac/institutes/grid.10419.3d schema:Organization
    56 https://www.grid.ac/institutes/grid.13648.38 schema:Organization
    57 https://www.grid.ac/institutes/grid.152326.1 schema:Organization
    58 https://www.grid.ac/institutes/grid.16872.3a schema:Organization
    59 https://www.grid.ac/institutes/grid.18886.3f schema:Organization
    60 https://www.grid.ac/institutes/grid.267309.9 schema:Organization
    61 https://www.grid.ac/institutes/grid.28803.31 schema:Organization
    62 https://www.grid.ac/institutes/grid.3575.4 schema:Organization
    63 https://www.grid.ac/institutes/grid.411326.3 schema:Organization
    64 https://www.grid.ac/institutes/grid.412966.e schema:Organization
    65 https://www.grid.ac/institutes/grid.413508.b schema:Organization
    66 https://www.grid.ac/institutes/grid.415214.7 schema:Organization
    67 https://www.grid.ac/institutes/grid.415930.a schema:Organization
    68 https://www.grid.ac/institutes/grid.416050.6 schema:Organization
    69 https://www.grid.ac/institutes/grid.416266.1 schema:Organization
    70 https://www.grid.ac/institutes/grid.417068.c schema:Organization
    71 https://www.grid.ac/institutes/grid.417581.e schema:Organization
    72 https://www.grid.ac/institutes/grid.417815.e schema:Organization
    73 https://www.grid.ac/institutes/grid.419619.2 schema:Organization
    74 https://www.grid.ac/institutes/grid.424926.f schema:Organization
    75 https://www.grid.ac/institutes/grid.428696.7 schema:Organization
    76 https://www.grid.ac/institutes/grid.4305.2 schema:Organization
    77 https://www.grid.ac/institutes/grid.430814.a schema:Organization
    78 https://www.grid.ac/institutes/grid.4494.d schema:Organization
    79 https://www.grid.ac/institutes/grid.476460.7 schema:Organization
    80 https://www.grid.ac/institutes/grid.477604.6 schema:Organization
    81 https://www.grid.ac/institutes/grid.4777.3 schema:Organization
    82 https://www.grid.ac/institutes/grid.497530.c schema:Organization
    83 https://www.grid.ac/institutes/grid.5132.5 schema:Organization
    84 https://www.grid.ac/institutes/grid.5477.1 schema:Organization
    85 https://www.grid.ac/institutes/grid.5590.9 schema:Organization
    86 https://www.grid.ac/institutes/grid.5645.2 schema:Organization
    87 https://www.grid.ac/institutes/grid.5650.6 schema:Organization
    88 https://www.grid.ac/institutes/grid.7107.1 schema:Organization
    89 https://www.grid.ac/institutes/grid.7692.a schema:Organization
    90 https://www.grid.ac/institutes/grid.9654.e schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...